The Translational Research Institute (TRI) is a unique, Australian-first initiative of ‘bench to bedside’ medical research. TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.
The concept of a major research institute on this site arose from the thinking of notable Queensland clinicians including Professor Brian Emmerson and Dr John Golledge, and the vision was conceived and brought to fruition by the clinicians and scientists of the four institutions who were its founding partners; The University of Queensland, Queensland University of Technology, Mater Medical Research Institute and Queensland Health.
The work conducted at TRI is translational research, a research process which involves teams of patients, clinicians and researchers working together to solve health challenges faster. The work is driven by the needs of patients, a question formed by a clinician and a solution sought by a scientist. While traditionally, clinicians and researchers worked separately, this improved method ensures patient needs are priority and that teams share knowledge which multiplies with every collaboration. These teams also create a feedback loop which is essential to the translational pathway. With the clinician and scientist working side by side with the patient, results are obvious immediately rather than via long reports which take time to read and interpret.
Several translational research projects are underway at TRI, including a Blood test for sub-tropical grass allergy, the Gardasil HPV Vaccine, Spectroscopy for high risk breast cancer, and Theranostic Development For Prostate Cancer.
In The Media
Patheon joins TRI vision to take medical research from ‘concept to commercialisation’. For the first time in Australia, biopharmaceuticals and treatments will be discovered, produced, clinically tested and manufactured to international standard at a single location. Patheon’s niche is its ability to provide an integrated single source for scale-up, commercial manufacture and finished dosage ╴a combination that makes the company an ideal partner for the TRI. Housed within TRI’s state-of-the-art bio-pharmaceutical manufacturing facility, Patheon represents the first major mammalian biopharmaceutical production facility in Australia.
BPA’s role as an industry development initiative of the Queensland Government is to generally foster Queensland’s and Australia’s biopharmaceutical industry. This role has focused initially on attracting an international biopharmaceutical contract manufacturer to establish operations in Australia.
Further details about the BDF can be found in the Application Guidelines and online Application Form on the Biopharmus website.
Queensland University of Technology (QUT) is a leading Australian university with a focus on world-class research and education. TRI's partner, QUT’s Institute of Health and Biomedical Innovation (IHBI), is a unique research facility that combines researchers across disciplines of health, science, technology and built environment and engineering to integrate their expertise in the areas of prevention, mind and body health, and recovery.
A member of the Group of Eight Universities Australia, University of Queensland (UQ) was the first tertiary education institute in Queensland. Reputed as a research-driven university, UQ’s Diamantina Institute – one of the state’s leading institutes in translational research into cancer, immunology and metabolic medicine – is a key partner of TRI.
The University of Queensland’s School of Medicine operates over many sites to promote and support teaching and research, partnering with Queensland Health and private health service providers at eleven Clinical Schools throughout Brisbane, in rural and remote facilities throughout Queensland, and internationally in Brunei and North America. Across the School, our research teams are embedded in hospital campuses and involve many of the 2,600 clinicians who hold joint UQ-Hospital appointments or honorary academic titles with our School.
The Princess Alexandra Hospital (PAH) involves its Centres for Health Research and Education as a research partner in TRI. With an enviable legacy and one of the state’s largest hospitals, PAH is renowned as being Queensland’s foremost teaching and research hospital. The PAH has responsibility for the management of the Queensland Liver Transplant Service, Queensland Eye Bank and the Queensland Bone Bank, as well as housing one of the major Pathology Queensland services.
Nestled within the Mater's hospitals at South Brisbane, Mater Reseach is driven by a 'bench to bedside' philosophy, where leading scientists work alongside doctors to turn basic scientific discovery into better treatment for patients. This world-class research has already contributed to significant advances in patient care and currently runs research programs in cancer, immunology, transplantation, mental health, pregnancy-related disorders, growth and development, diabetes and obesity - with high-profile research being undertaken in flood and disaster recovery, preventing stillbirths and improving our understanding and treatment of cancer.